Omicron Antigens Now Available
We offer whole Spike, S1 and RBD antigens for the SARS-CoV-2 Omicron (B.1.1.529) variant. Our Spike antigens exhibit full glycosylation and proper folding, ideal for developing high quality immunoassays and raising highly specific antibodies.
About the Omicron Variant
The novel B.1.1.529 SARS-CoV-2 variant was designated Omicron on the 26th November, following its increasing prevalence in South Africa. Harbouring more than 30 mutations in its Spike gene, the principal concerns surround Omicron’s infectivity, virulence and ability to circumvent vaccine protection.
To understand the threat that Omicron poses, researchers have begun closely tracking its spread and investigating all facets of its biology. The nature of research carried out so far follows that of other variants, including analysis of epidemiological data, in vitro binding studies and computational modelling. So far, little is known about the new variant. However, parallels with other variants and emerging data are beginning to give an indication.
We now offers three Spike antigens for the SARS-CoV-2 Omicron variant:
Our trimeric whole Spike antigen is stabilised as a pre-fusion trimer via six amino acid (HexaPro) changes in the S2 subunit, in addition to a GSAS mutation in the furin cleavage site and a His-Strep-tag at the C-terminus for ease of purification.
Our Spike receptor-binding domain (RBD) antigen includes residues 319-542 of the full Spike sequence and a C-terminal His-tag for ease of purification.